Abbott Laboratories (NYSE:ABT – Get Free Report) announced its quarterly earnings results on Thursday. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03, FiscalAI reports. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the firm earned $1.26 EPS. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories updated its Q3 2026 guidance to 1.380-1.46 EPS and its FY 2026 guidance to 5.450-5.60 EPS.
Abbott Laboratories Stock Performance
Shares of ABT opened at $89.27 on Thursday. The company has a 50-day moving average of $89.33 and a two-hundred day moving average of $102.36. The stock has a market cap of $155.49 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 1.53 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.
Abbott Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.
Wall Street Analyst Weigh In
Read Our Latest Report on Abbott Laboratories
Abbott Laboratories News Summary
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Analysts expect Abbott’s upcoming Q2 results to show healthy revenue and earnings growth, supported by strong performance in Diagnostics, Devices and Emerging Pharmaceutical/EPD segments. Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition
- Positive Sentiment: Coverage around Abbott’s cancer diagnostics strategy highlights longer-term growth potential, with management continuing to invest in improving tests and expanding the business after the Exact Sciences acquisition. Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’
- Positive Sentiment: Analysts are still recommending investors retain Abbott shares for now, citing emerging-market pharmaceutical growth and continued innovation in nutrition as potential supports for the stock. Reasons to Retain Abbott Stock in Your Portfolio for Now
- Neutral Sentiment: Market commentary says Abbott is one of the names investors are watching as earnings season begins, but the article is mainly a watchlist note rather than fresh company-specific news. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
- Neutral Sentiment: Another brief market note also flags Abbott ahead of earnings, reinforcing that the stock is being traded around the upcoming results. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
- Negative Sentiment: Risks remain from macro pressure and foreign exchange swings, which could weigh on results even if core business trends stay healthy. Reasons to Retain Abbott Stock in Your Portfolio for Now
- Negative Sentiment: Nutrition remains a drag in the near term, and some coverage notes that this segment could limit upside if other divisions do not fully offset it. Abbott’s Q2 Earnings on Deck: How Should You Play the Stock Now?
Insiders Place Their Bets
In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intesa Sanpaolo Wealth Management acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $29,000. Turning Point Benefit Group Inc. purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at $39,000. SWAN Capital LLC increased its stake in shares of Abbott Laboratories by 53.1% in the fourth quarter. SWAN Capital LLC now owns 300 shares of the healthcare product maker’s stock worth $38,000 after acquiring an additional 104 shares during the last quarter. Wealth Watch Advisors INC raised its holdings in shares of Abbott Laboratories by 121.6% during the fourth quarter. Wealth Watch Advisors INC now owns 359 shares of the healthcare product maker’s stock worth $45,000 after acquiring an additional 197 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new stake in Abbott Laboratories during the fourth quarter valued at $49,000. 75.18% of the stock is owned by hedge funds and other institutional investors.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Recommended Stories
- Five stocks we like better than Abbott Laboratories
- Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money
- Cintas Keeps Beating Expectations—And the Story Isn’t Over
- Which Storage Stock Is Best Positioned to Win the AI Memory War?
- Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
